Powered By Google

Potter Lab: Publications


    2012

  • Kim J-K, Yuan H, Nie J, Leggas M, Potter PM, Rinehart J, Jay M, Lu X. High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery. Small 2012 (in press).

  • Ulrich DL, Lynch J, Wang Y, Fukuda Y, Nachagari D, Du G, Sun D, Fan Y, Tsurkan L, Potter PM, Rehg JE, Schuetz J. The ATP-dependent mitochondrial porphyrin importer ABCB6 protects against phenylhydrazine toxicity. J Biol Chem 2012 (in press).


  • 2011

  • Crow JA, Bittles V, Herring KL, Borazjani A, Potter PM, Ross M. Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon. Toxicol Appl Pharmacol 2012 (in press).

  • Yu X, Wierdl M, Potter PM, Wadkins RM. Global and local molecular dynamics of a bacterial carboxylesterase provide insight into its catalytic mechanism. J Mol Model 2012 (in press).

  • Parkinson E, Hyatt JL, Hicks LD, Edwards CC, Yang B, Potter PM. Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones. Bioorg Med Chem 19:4635-43, 2011.

  • Edwards JE, Khumbar A, Roberts A, Hemmert AC, Edwards CC, Potter PM, Redinbo MR. Immobilization of active human carboxylesterase 1 in biomimetic silica nanoparticles. Biotechnol Prog 27:863-9, 2011.

  • Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM. Sudemycins, novel small molecule analogues of FR904164, induce alternative gene splicing. ACS Chemical Biology 2011 (in press).

  • Hemmert AC, Otto TC, Chica RA, Wierdl M, Lewis SL, Edwards CC, Tsurkan L, Cashman JR, Mayo SL, Potter PM, Cerasoli DM, Redinbo MR. Nerve agent hydrolysis activity designed into a human drug metabolism enzyme. PLoS One 2011 (in press).

  • Hatfield MJ, Tsurkan L, Garrett M, Shaver T, Edwards CC, Hyatt JL, Hicks LD, Potter PM. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 81:24-31, 2011. PMCID: PMC2991631.


  • 2010

  • Young BM, Hyatt JL, Bouck DC, Chen T, Hanumesh P, Price J, Boyd VA, Potter PM, Webb TR. Structure-activity relationships of substituted 1-Pyridyl-2-phenyl-1,2-ethanediones: potent, selective carboxylesterase inhibitors. J Med Chem 53:8709-8715, 2010. PMCID: PMC3022373.

  • Hatfield MJ, Tsurkan L, Hyatt JL, Yu X, Edwards CC, Hicks LD, Wadkins RM, Potter PM. Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. Br J Pharmacol 160:1916-1928, 2010. PMCID: PMC2958638.


  • 2009

  • Hicks LD, Hyatt JL, Stoddard S, Tsurkan L, Edwards CC, Wadkins RM, Potter PM. Improved, selective human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan; CPT-11) toxicity. J Med Chem 52:3742-3752, 2009. PMCID: PMC2780016.


  • 2008

  • Wierdl M, Tsurkan L, Hyatt JL, Hatfield MJ, Edwards CC, Danks MK, Redinbo MR, Potter PM. An improved human carboxylesterase for use in enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 15:183-192, 2008.


  • 2007

  • Hyatt JL, Wadkins RM, Tsurkan L, Hicks L, Hatfield MJ, Edwards CC, Ross CR, Cantalupo SA, Crundwell G, Guy RK, Potter PM. Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem 50:5727-5734, 2007.

  • Danks MK Yoon KJ,  Bush RA, Remack JS, Wierdl M, Tsurkan L, Kim SU, Garcia E, Metz M, Najbauer J, Potter PM, Aboody KS, Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 67:22-25, 2007.


  • 2006

  • Aboody KS, Bush RA, Garcia E, Metz M, Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S, Kim SU, Glackin C, Potter PM, Danks MK. Development of a tumor-selective approach to treat metastatic cancer. PLoS One 1:e23; 1-10, 2006. Editorials PLoS Medicine 3:e482, 2182-2183, 2006; Nature Clin Practice Oncology 4:279-80, 2007; PLoS Medicine 3: e482, 2006.

  • Hyatt JL, Tsurkan L, Wierdl M, Edwards CC, Danks MK, Potter PM. Intracellular inhibition of carboxylesterases by benzil: Modulation of CPT-11 cytotoxicity. Mol Cancer Therap 5:2281-2288, 2006.


  • 2005

  • Harel M, Hyatt JL, Brumshtein B, Morton CL, Wadkins RM, Silman I, Sussman JL, Potter PM. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase. Chem Biol Int 157-158:153-157, 2005.

  • Wadkins RM, Hyatt JL, Wei X, Yoon KJP, Wierdl M, Edwards CC, Morton CL, Obenauer JC, Damodaran K, Beroza P, Danks MK, Potter PM. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 48:2906-2915, 2005.


  • 2004

  • Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, Damodaran K, Beroza P, Danks MK, Potter PM. Identification of novel selective human intestinal carboxylesterase inhibitors for the amelioration of CPT-11 induced diarrhea: Synthesis, QSAR analysis, mechanism of action and biological activity. Mol Pharmacol 65:1336-1343, 2004.


  • 2003

  • Stubdhal H, Perin N, Lemmon M, Holman P, Bauzon M, Potter PM, Danks MK, Fattaey A, Dubensky T, Johnson L. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit liver carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res 63:6900-6908, 2003.

  • Wierdl M, Wall A, Morton CL, Danks MK, Schuetz JD, Potter PM. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override BCRP-mediated drug resistance. Mol Pharm 64:279-288, 2003.

  • Bencharit S, Morton CL, Hyatt, JL, Kuhn P, Danks MK, Potter PM, Redinbo MR. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: From binding promiscuity to selective inhibition. Chem and Biol 10:341-349, 2003. Preview, Chem and Biol 10:295-297, 2003. Review, Nat Rev Drug Discov 2: 511, 2003.


  • 2002

  • Bencharit S, Morton CL, Howard-Williams EL, Danks, MK, Potter PM, Redinbo MR. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nature Struct Biol 9:337-342, 2002


  • 2001

  • Meck M, Wierdl M, Wagner L, Burger R, Harris LC, Potter PM, Danks MK. A VDEPT approach to purging neuroblastoma cells from hematopoeitic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 61:5083-5089, 2001.

  • Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, Potter PM. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 61:5078-5082, 2001.


  • 2000

  • Khanna R, Morton CL, Wierdl M, Danks MK, Potter PM. Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res 60:4725-4728, 2000.


  • 1999

  • Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, Pawlik CA, Houghton PJ, Potter PM. Comparison of activation of CPT-11 by rabbit and human carboxylesterase for use in enzyme/prodrug therapy. Clin Cancer Res 5:917-924, 1999.

  • Morton CL, Wadkins R, Danks MK, Potter PM: The anticancer drug CPT-11 is a potent inhibitor of acetylcholinesterases but is activated to SN-38 by butyrylcholinesterases. Cancer Res 59:1458-1463, 1999.


  • 1998

  • Potter PM, Wolverton JS, Morton CL, Wierdl M, Danks MK. Cellular localization domains of a rabbit and a human carboxylesterase: influence on CPT-11 metabolism by the rabbit enzyme. Cancer Res 58:3627-3632, 1998.

  • Potter PM, Pawlik CA, Morton CL, Naeve CW, Danks MK. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug CPT-11. Cancer Res 58:2646-2651, 1998.